MINNEAPOLIS (October 10, 2017) – Today, OneOme announced it has been named a finalist for the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards in the Healthcare category. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership. OneOme’s RightMed® pharmacogenomic solution identifies how a patient's DNA and current medications may affect their response to medications.
“OneOme was created to address the challenge of making pharmacogenomics, a potentially life-saving science, available to everyone,” Paul Owen, CEO of OneOme said. “Our mission is to deliver the most cost-effective, high quality pharmacogenomic testing and tools for all providers across the globe to use in everyday patient care. OneOme appreciates MHTA’s recognition of our leadership in precision medicine and healthcare technology.”
OneOme was co-developed with Mayo Clinic and is backed by early-stage venture firm Invenshure, a Minnesota-based healthcare incubator, and Mayo Clinic. OneOme’s RightMed comprehensive test has the potential to address the crisis of adverse drug reactions and drug ineffectiveness by analyzing how a person’s genes may predict their response to medications. OneOme’s pharmacogenomic testing and clinical support tools are easy-to-use, intuitive and ready to be integrated into clinical practices. The RightMed comprehensive test covers hundreds of medications for a wide range of medical conditions, including psychiatric conditions, cancer, chronic pain, cardiovascular disease, and more and it can be integrated into electronic medical records (EMRs).
To date, over 450 locations from more than 22 different countries have ordered OneOme’s RightMed test. OneOme continues to build research and commercial partnerships across the globe, including recent partnerships in Canada, Australia, Mexico, Japan, Hong Kong, and Macau.
Presented by the MHTA, the Tekne Awards annually recognize Minnesota’s best and brightest technology users and developers in innovation, development, education, commercialization, and management. The awards ceremony takes place November 15 at the Minneapolis Convention Center. More information about the awards and finalists is available at tekneawards.org.
“Each year, MHTA seeks out companies and people leading the way in innovation in Minnesota,” Margaret Anderson Kelliher, president and CEO of MHTA, said. “These advancements are changing the way people all over the world live and work, and the Tekne Awards recognize those achievements.”
About Minnesota High Tech Association (MHTA)
MHTA is an innovation and technology association united in fueling Minnesota’s prosperity. We help bring together the people of Minnesota’s technology ecosystem and lead the charge in directing technology issues to Minnesota’s state capitol. MHTA is the only membership organization that represents Minnesota’s entire technology-based economy. MHTA members include organizations of every size − involved in virtually every aspect of technology creation, production, application and education in Minnesota. Find out more online at http://www.mhta.org or follow MHTA on Twitter at http://twitter.com/MHTA.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.
Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.